US 7,616,692

Application 10/933,956 · Granted Nov 10, 2009

Hybrid motion vector prediction for interlaced forward-predicted fields

Estimated expiration

June 3, 2028

1y 194d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
May 27, 2004
+ 20 years
May 27, 2024
PTA +1468d
Jun 3, 2028
No TD
—
Final
Jun 3, 2028

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
September 2, 2004
Earliest effective filing
May 27, 2004
Issue date
November 10, 2009
PTA
+1468 days
Base expiry (before PTA)
May 27, 2024

May 27, 2004 + 20 years = May 27, 2024 + 1468 PTA days = June 3, 2028

  • Continuation-in-part of application 10/857,473, filed May 27, 2004, issued as US 7,567,617
  • PRO60/501,081 — Provisional — not used for base term
  • PRO60/501,081 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 10/933,956 · US 7,616,692

PatentReply compiles the prosecution history behind US 7,616,692: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US7616692

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.